TikTok claims Trump forced order US business sell a day before the extension ends: This Thursday, November 12, the 90-day deadline that the Executive Order of US President Donald Trump gave to the Chinese company Bytedance to sell its American subsidiary of the application of short videos TikTok, which Trump considered a Chinese cyber espionage tool, under threat of prohibiting him from doing business in the United States.
Despite the agreement in principle that TikTok established with Oracle to be its technology partner in a new subsidiary for the u.s. territory, called the TikTok Global, of the that the american company would have 12.5% of the shareholding and speculated that it would bag, this matter remains pending, among other matters, for the controversy about its algorithm of recommendation videos.
With Donald Trump's departure from the White House secured by the victory of Democrat Joe Biden and a day before the three-month deadline given by the executive order expires, TikTok counteracts with a petition in the Court of Appeal of the District of Columbia (United States) in which it asks that the Trump order be reviewed under the pretext that it violates the constitutional rights of the company, according to the Financial Times.
At the same time, TikTok has asked the Committee on foreign investments in the United States (CFIUS) to activate the extra 30 days of Deadline that included the order, arguing that it is facing "continuous new requests" and is not receiving "clarity" on whether its proposals have been accepted, according to Bytedance sources.
"In the last two months since the president gave his preliminary approval we have offered detailed solutions to finalize the agreement, but we have not received substantial response on our extensive privacy and security policies," the company notes in a statement.
TikTok claims Trump forced order US business sell
ByteDance's latest proposal has been to restructure TikTok in the United States into a new company that would be owned by Oracle, the supermarket chain Walmart —very interested in TikTok to shore up its digital strategy towards e— commerce-and Bytedance's American investors.
On the other hand, it is unknown whether the new tenant of the White House, Democrat Joe Biden, will decide to continue with the provisions of his Republican predecessor or take a different course with respect to TikTok.
A technology adviser to the new president-elect told CNBC that it is "too early" to know what Biden's stance will be on TikTok, although during his election campaign the Democratic candidate asked his employees to delete the application of short videos from their work and personal phones for security reasons.
The situation of this application is part of a much larger package of issues, including US-China relations, deteriorated during the Trump administration, which has vetoed not only ByteDance, but also the mobile and electronic components manufacturer Huawei, which has had to stop its chip production by the US government's vetoes.
TikTok claims Trump forced order US business sell
The scientific director of Pfizer confesses that they are already thinking about a new vaccine against coronavirus by 2021: this is how they plan to overcome the great limitation of the current version
Pfizer is already working on a new coronavirus vaccine that could avoid its biggest problem of having to stay in extremely cold temperatures.
"We are thinking about some possibilities for the next generation of vaccines," explains Mikael Dolsten, Chief Scientific Officer of Pfizer, to Business Insider in an interview. "I think next year we will launch a powder vaccine for COVID-19."
A powder version would not require the heavy cold chain storage that is a key limitation of Pfizer's current candidate, which needs to be stored at minus 70 degrees Celsius, which can further complicate the distribution of the vaccine around the planet.
While the United States and other developed countries are likely to be able to create the infrastructure needed to deliver a frozen vaccine, it would be more difficult to immunize people living in the poorest areas of the world. And even in America, many state officials are not sure how they will be able to cope with storage and transportation requirements.
Pfizer's coronavirus vaccine candidate has proven to have a high level of efficacy in the final stage of clinical trials, the New York drugmaker announced Monday. A two-dose regimen of the vaccine —another added complication for distribution, since doses are inoculated 3 weeks apart— seems to be more than 90% effective in protecting people against COVID-19, according to the company.
Pfizer's operations and logistics teams have been preparing for this challenge for the past few months. The company will send the vaccine by air and land using dry ice, along with reusable GPS temperature control devices, as executives explained in a presentation of the company to investors last September.
Still, many hospital systems lack storage facilities to keep the vaccine cold enough, including some of the most reputable hospitals in the United States, such as the Mayo Clinic in Rochester, Minnesota, Reuters reports.
"We are a major medical center and we do not have storage capacity like this," Dr. Gregory Poland, a virologist at the Mayo Clinic, tells Reuters. "That will be so for everyone. It is a logistical obstacle."
Although the vaccine has not yet been approved and has not even applied for approval from regulatory authorities, the Chief Scientist of Pfizer has highlighted the potential of a second-generation version, which could have less demanding temperature requirements.
A powder version could arrive next year without requiring super cold storage, Dolsten has assured, although without specifying at what exact temperature it would have to be stored.
"We believe that already in 2021 we could develop a powder form that could only need cooling," he assured. "That would simplify everything."
Pfizer has worked with German biotech BioNTech to develop its coronavirus vaccine using a new technology platform called messenger RNA. Dolsten predicts that this would not be the duo's last mRNA work in infectious disease vaccines, given the real possibility of future epidemics.
"I don't think this is the end of the coronavirus invasion," he notes. "There are likely to be other coronaviruses like the ones we have seen since 2003 with SARS, followed by MERS and now COVID-19," Dolsten sentences.